Horizon Discovery Inks Alliance with Agios Pharmaceuticals | GenomeWeb
NEW YORK (GenomeWeb News) – Horizon Discovery said today that it has signed two agreements with cancer startup Agios Pharmaceuticals related to its X-Man cell-line technology.
 
The Cambridge, UK-based firm said that it has licensed certain X-Man cell lines, including major cancer-causing genes and their matched normal genetic backgrounds. In addition, it said that it would screen a number of Agios lead compounds on a wide panel of genotypes.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.